Kura Oncology, Inc. (NASDAQ:KURA) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Kura Oncology, Inc. (NASDAQ:KURA) has been given an average rating of “Moderate Buy” by the eight research firms that are covering the company, Marketbeat reports. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $28.28.

KURA has been the subject of a number of research analyst reports. Wedbush reaffirmed an “outperform” rating and issued a $37.00 price target on shares of Kura Oncology in a research note on Wednesday, February 28th. HC Wainwright reaffirmed a “buy” rating and set a $32.00 price objective on shares of Kura Oncology in a research note on Monday. JMP Securities lifted their price target on Kura Oncology from $22.00 to $32.00 and gave the company a “market outperform” rating in a report on Wednesday, January 31st. Finally, StockNews.com downgraded Kura Oncology from a “hold” rating to a “sell” rating in a research note on Monday, April 15th.

Insider Activity at Kura Oncology

In related news, insider Teresa Brophy Bair sold 2,053 shares of the firm’s stock in a transaction dated Monday, January 29th. The stock was sold at an average price of $17.80, for a total value of $36,543.40. Following the transaction, the insider now owns 68,979 shares in the company, valued at $1,227,826.20. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, insider Teresa Brophy Bair sold 2,053 shares of Kura Oncology stock in a transaction on Monday, January 29th. The stock was sold at an average price of $17.80, for a total transaction of $36,543.40. Following the completion of the sale, the insider now directly owns 68,979 shares of the company’s stock, valued at $1,227,826.20. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, SVP Thomas James Doyle sold 2,318 shares of the firm’s stock in a transaction dated Monday, January 29th. The stock was sold at an average price of $17.80, for a total value of $41,260.40. Following the transaction, the senior vice president now owns 48,093 shares in the company, valued at approximately $856,055.40. The disclosure for this sale can be found here. Insiders sold 5,867 shares of company stock valued at $104,433 over the last ninety days. 5.50% of the stock is owned by insiders.

Institutional Trading of Kura Oncology

Large investors have recently made changes to their positions in the company. Signaturefd LLC boosted its position in shares of Kura Oncology by 40.4% during the fourth quarter. Signaturefd LLC now owns 5,038 shares of the company’s stock worth $72,000 after buying an additional 1,449 shares during the period. China Universal Asset Management Co. Ltd. boosted its position in shares of Kura Oncology by 352.6% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,590 shares of the company’s stock valued at $124,000 after acquiring an additional 6,692 shares during the period. Saxon Interests Inc. acquired a new position in shares of Kura Oncology during the 1st quarter worth approximately $201,000. Pale Fire Capital SE acquired a new stake in Kura Oncology during the third quarter worth approximately $92,000. Finally, E Fund Management Co. Ltd. increased its position in shares of Kura Oncology by 12.2% in the third quarter. E Fund Management Co. Ltd. now owns 11,929 shares of the company’s stock worth $109,000 after purchasing an additional 1,301 shares during the period.

Kura Oncology Stock Up 3.0 %

Shares of Kura Oncology stock opened at $18.73 on Wednesday. Kura Oncology has a twelve month low of $7.41 and a twelve month high of $24.17. The stock has a market capitalization of $1.43 billion, a price-to-earnings ratio of -9.00 and a beta of 0.85. The company has a current ratio of 12.26, a quick ratio of 12.26 and a debt-to-equity ratio of 0.02. The business’s 50 day simple moving average is $20.73 and its 200-day simple moving average is $15.35.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings results on Tuesday, February 27th. The company reported ($0.55) EPS for the quarter, beating the consensus estimate of ($0.56) by $0.01. During the same quarter last year, the business posted ($0.49) earnings per share. Equities research analysts forecast that Kura Oncology will post -2.35 earnings per share for the current year.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.